Erschienen in:
02.11.2021 | Research Letter
Occurrence and response to treatment of Graves’ disease after COVID vaccination in two male patients
verfasst von:
Luigi di Filippo, Laura Castellino, Andrea Giustina
Erschienen in:
Endocrine
|
Ausgabe 1/2022
Einloggen, um Zugang zu erhalten
Excerpt
COVID-19 had dramatic impact worldwide and various vaccines anti-SARS-CoV-2 were rapidly developed (
https://covid19.who.int/). Despite a good safety profile in clinical trials, rare and severe side effects of vaccines have been reported, including thyroid dysfunctions [
1]. In particular, occurrence of Graves’ disease (GD) post-vaccination with Tozinameran (Pfizer–BioNTech) was reported in three female subjects and only one male prevalently in young-adult age [
2,
3] somewhat reflecting the epidemiological age and sex distribution of the disease [
4]. Therefore, based on the previously reported cases a casual relationship between vaccination and occurrence of GD could not be excluded. Moreover, very little information is available on the clinical behavior of this possibly vaccine-related GD and potential occurrence of GD after COVID-19 vaccines other than Tozinameran. We here report the occurrence and the response to treatment of GD in two male patients after Vaxzevria (Oxford-AstraZeneca) SARS-CoV-2 vaccinations. …
